All In Biotech

Drug Trial Radar · NCT04959032

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 592 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

592

Actual

Start

Jul 8, 2021

Primary completion

Jul 25, 2024

Study completion Aug 7, 2024

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Jul 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).

Conditions

  • Schizophrenia

Interventions

  • Lumateperone 42 mgDrug

    Lumateperone 42 mg capsules administered orally, once daily.

  • PlaceboDrug

    Matching capsules administered orally, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Symptom Relapse During the Double-blind Treatment PhaseTime frame: Number of days from the randomization date to the first relapse date up to 26 weeks.

Locations

43 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Little Rock, Arkansas

  • Clinical Site

    Bellflower, California

  • Clinical Site

    Cerritos, California

  • Clinical Site

    Culver City, California

  • Clinical Site

    Garden Grove, California

  • Clinical Site

    Lemon Grove, California

  • Clinical Site

    Montclair, California

  • Clinical Site

    Orange, California

  • Clinical Site

    Hollywood, Florida

  • Clinical Site

    Miami Lakes, Florida

  • Clinical Site

    Oakland Park, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Chicago, Illinois

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    St Louis, Missouri

  • Clinical Site

    Las Vegas, Nevada

  • Clinical Site

    Berlin, New Jersey

  • Clinical Site

    North Canton, Ohio

  • Clinical Site

    Austin, Texas

  • Clinical Site

    DeSoto, Texas

  • Clinical Site

    Richardson, Texas

  • Clinical Site

    Burgas, Bulgaria

  • Clinical Site

    Kardzhali, Bulgaria

  • Clinical Site

    Kazanlak, Bulgaria

  • Clinical Site

    Lovech, Bulgaria

  • Clinical Site

    Novi Iskar, Bulgaria

  • Clinical Site

    Pleven, Bulgaria

  • Clinical Site

    Plovdiv, Bulgaria

  • Clinical Site

    Rousse, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Targovishte, Bulgaria

  • Clinical Site

    Tsarev Brod, Bulgaria

  • Clinical Site

    Tserova Koria, Bulgaria

  • Clinical Site

    Veliko Tarnovo, Bulgaria

  • Clinical Site

    Vratsa, Bulgaria

  • Clinical Site

    Gdansk, Poland

  • Clinical Site

    Gdansk, Poland

  • Clinical Site

    Gorlice, Poland

  • Clinical Site

    Tuszyn, Poland

  • Clinical site

    Belgrade, Serbia

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.